Jury says Bayer must pay $80 million to man in Roundup cancer trial

The Bayer AG logo sits behind silhouetted members of the management board during the company's annual general meeting in Bonn, Germany, May 25, 2018.

Krisztian Bocsi | Bloomberg | Getty Images

The Bayer AG logo sits behind silhouetted members of the management board during the company’s annual general meeting in Bonn, Germany, May 25, 2018.

A U.S. jury on Wednesday awarded $80 million to a man who claimed his use of Bayer’s glyphosate-based weed killer Roundup caused his cancer, from the latest legal setback for the company facing thousands of similar lawsuits.

The jury in San Francisco federal court said the company was liable for plaintiff Edwin Hardeman’s non-Hodgkin’s lymphoma.

the idea awarded $5 million in compensatory damages as well as also $75 million in punitive damages to Hardeman after finding in which Roundup was defectively designed, in which Monsanto failed to warn of the herbicide’s cancer risk as well as also in which the company acted negligently.

Bayer bought Roundup maker Monsanto last year for $63 billion.

The company denies the allegations, saying decades of studies by independent scientists have shown glyphosate as well as also Roundup to be safe for human use.

The trial will be only the second of more than 11,0 Roundup lawsuits set to go to trial from the United States. Previous litigation setbacks as well as also a prior jury verdict against the company have sent Bayer shares plunging.

The verdict comes roughly a week after the same jury on March 19 found Roundup to have been a “substantial factor” in causing Hardeman’s cancer, allowing the trial to proceed into a second phase to determine liability as well as also damages. Bayer shares fell more than 12 percent after last week’s jury finding.

Official correction: This specific story has been updated to reflect in which the jury awarded over $80 million to the man, including $5 million in compensatory damages. Reuters misstated the figures in a previous type of its story.